Francesco Franchi Selected Research

thrombin receptor peptide SFLLRNP

9/2022	Platelet P2Y12 inhibiting therapy in adjunct to vascular dose of rivaroxaban or aspirin: a pharmacodynamic study of dual pathway inhibition vs. dual antiplatelet therapy.
8/2022	Pharmacodynamic Profiles of Dual-Pathway Inhibition with or without Clopidogrel versus Dual Antiplatelet Therapy in Patients with Atherosclerotic Disease.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Francesco Franchi Research Topics

Disease

23	Hemorrhage 12/2022 - 01/2014
21	Coronary Artery Disease (Coronary Atherosclerosis) 11/2022 - 10/2013
19	Acute Coronary Syndrome 03/2022 - 08/2013
14	Thrombosis (Thrombus) 09/2022 - 08/2013
13	Diabetes Mellitus 11/2022 - 01/2014
9	Myocardial Infarction 03/2022 - 01/2014
8	ST Elevation Myocardial Infarction 01/2022 - 09/2015
4	Chronic Renal Insufficiency 11/2022 - 06/2015
3	Cardiovascular Diseases (Cardiovascular Disease) 11/2020 - 04/2015
2	Ischemic Stroke 01/2022 - 01/2022
2	Unstable Angina 01/2022 - 01/2022
2	Type 2 Diabetes Mellitus (MODY) 09/2016 - 09/2014
2	Heart Failure 10/2013 - 08/2013
1	Stroke (Strokes) 01/2021
1	Atrial Fibrillation 12/2019
1	Embolic Stroke 01/2018
1	Peripheral Arterial Disease 01/2018
1	Coma (Comas) 02/2017
1	Non-ST Elevated Myocardial Infarction 05/2016
1	Vascular Diseases (Vascular Disease) 02/2014

Drug/Important Bio-Agent (IBA)

26	Clopidogrel (Plavix)FDA Link 03/2022 - 01/2014
25	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 11/2021 - 10/2013
23	TicagrelorIBA 11/2022 - 09/2015
15	Prasugrel Hydrochloride FDA Link 03/2022 - 04/2014
12	2'- deoxythymidylyl- (3'- 5')- 2'- deoxyadenosine (d(AT))IBA 12/2022 - 05/2016
7	Purinergic P2Y Receptor AntagonistsIBA 01/2019 - 10/2013
6	Thrombin FDA Link 09/2022 - 01/2014
5	vorapaxarIBA 01/2020 - 01/2014
5	AnticoagulantsIBA 01/2020 - 07/2015
4	Adenosine Diphosphate (ADP)IBA 08/2022 - 10/2013
3	Pharmaceutical PreparationsIBA 05/2016 - 09/2015
2	thrombin receptor peptide SFLLRNPIBA 09/2022 - 08/2022
2	omega-Chloroacetophenone (Mace)IBA 03/2022 - 01/2022
2	Cytochrome P-450 CYP2C19IBA 01/2022 - 01/2021
2	cangrelorIBA 01/2022 - 01/2019
2	Proteins (Proteins, Gene)FDA Link 01/2020 - 03/2016
2	TabletsIBA 01/2017 - 05/2016
1	Cyclooxygenase 1IBA 09/2022
1	Thromboplastin (Tissue Factor)IBA 09/2022
1	Diphosphates (Pyrophosphates)IBA 08/2022
1	Arachidonic Acid (Vitamin F)IBA 08/2022
1	CollagenIBA 08/2022
1	insulin receptor-related receptor (IRR)IBA 03/2022
1	Cytochrome P-450 Enzyme System (Cytochrome P450)IBA 01/2021
1	IsoenzymesIBA 01/2021
1	SugarsIBA 01/2021
1	APTIBA 01/2020
1	edoxabanIBA 01/2020
1	Morphine (MS Contin)FDA LinkGeneric 01/2019
1	Narcotic Antagonists (Opioid Antagonists)IBA 01/2019
1	methylnaltrexone FDA Link 01/2019
1	Fibrinolytic Agents (Antithrombotic Agents)IBA 01/2018
1	Vitamin K FDA Link 12/2017
1	TroponinIBA 03/2017
1	FibrinIBA 03/2016
1	Dabigatran FDA Link 03/2016
1	Fibrinogen (Factor I)FDA Link 04/2015
1	Platelet Aggregation Inhibitors (Antiplatelet Drugs)IBA 01/2015
1	N 30IBA 09/2014
1	CotinineIBA 02/2014
1	EicosanoidsIBA 01/2014
1	Peptide Hydrolases (Proteases)FDA Link 01/2014
1	Thromboxane A2 (A2, Thromboxane)IBA 01/2014
1	Glycoproteins (Glycoprotein)IBA 08/2013

Therapy/Procedure

37	Therapeutics 03/2022 - 08/2013
24	Percutaneous Coronary Intervention 01/2022 - 08/2013
8	Stents 03/2022 - 05/2014
4	Secondary Prevention 01/2018 - 01/2016
2	Cardiac Resynchronization Therapy 10/2013 - 08/2013
1	Drug-Eluting Stents 11/2021
1	Polypharmacy 11/2020
1	Intravenous Administration 01/2019
1	Drug Therapy (Chemotherapy) 01/2017
1	Operative Surgical Procedures 11/2014
1	Perioperative Period 11/2014